Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 4
2013 1
2014 3
2015 2
2016 5
2017 2
2018 2
2019 1
2020 3
2021 1
2022 10
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Makker V, et al. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045221 Clinical Trial.
Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up.
Lindskrog SV, Birkenkamp-Demtröder K, Nordentoft I, Laliotis G, Lamy P, Christensen E, Renner D, Andreasen TG, Lange N, Sharma S, ElNaggar AC, Liu MC, Sethi H, Aleshin A, Agerbæk M, Jensen JB, Dyrskjøt L. Lindskrog SV, et al. Among authors: elnaggar ac. Clin Cancer Res. 2023 Dec 1;29(23):4797-4807. doi: 10.1158/1078-0432.CCR-23-1860. Clin Cancer Res. 2023. PMID: 37782315 Free PMC article.
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, Bradley W, Sachdev J, Sirard CA, O'Malley DM, Birrer M. Arend R, et al. Among authors: elnaggar ac. Gynecol Oncol. 2023 May;172:82-91. doi: 10.1016/j.ygyno.2023.03.013. Epub 2023 Mar 29. Gynecol Oncol. 2023. PMID: 37001446 Clinical Trial.
In reply.
ElNaggar AC. ElNaggar AC. Obstet Gynecol. 2014 Jan;123(1):184. doi: 10.1097/AOG.0000000000000065. Obstet Gynecol. 2014. PMID: 24463683 No abstract available.
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Randall LM, O'Malley DM, Monk BJ, Coleman RL, Gaillard S, Adams S, Duska LR, Dalton H, Holloway RW, Huang M, Chon HS, Cloven NG, ElNaggar AC, O'Cearbhaill RE, Waggoner S, Tarkar A, Striha A, Nelsen LM, Baines A, Samnotra V, Konstantinopoulos PA. Randall LM, et al. Among authors: elnaggar ac. Gynecol Oncol. 2023 Nov;178:161-169. doi: 10.1016/j.ygyno.2023.10.005. Epub 2023 Oct 25. Gynecol Oncol. 2023. PMID: 37890345 Clinical Trial.
Same-day discharge after robotic surgery for endometrial cancer.
Zhang N, Wilson B, Enty MA, Ketch P, Ulm MA, ElNaggar AC, Daily L, Tillmanns T. Zhang N, et al. Among authors: elnaggar ac. J Robot Surg. 2022 Jun;16(3):543-548. doi: 10.1007/s11701-021-01253-0. Epub 2021 Jul 8. J Robot Surg. 2022. PMID: 34236587 Review.
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM. Armstrong DK, et al. Among authors: elnaggar ac. J Natl Compr Canc Netw. 2019 Aug 1;17(8):896-909. doi: 10.6004/jnccn.2019.0039. J Natl Compr Canc Netw. 2019. PMID: 31390583
Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies.
Jang A, Lanka SM, Jaeger EB, Lieberman A, Huang M, Sartor AO, Mendiratta P, Brown JR, Garcia JA, Farmer T, Sudhaman S, Mahmood T, Pajak N, Calhoun M, Dutta P, ElNaggar A, Liu MC, Barata PC. Jang A, et al. Among authors: elnaggar a. JCO Precis Oncol. 2023 Jul;7:e2300131. doi: 10.1200/PO.23.00131. JCO Precis Oncol. 2023. PMID: 37467457
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Friedman CF, D'Souza A, Bello Roufai D, Tinker AV, de Miguel M, Gambardella V, Goldman J, Loi S, Melisko ME, Oaknin A, Spanggaard I, Shapiro GI, ElNaggar AC, Panni S, Ravichandran V, Frazier AL, DiPrimeo D, Eli LD, Solit DB. Friedman CF, et al. Among authors: elnaggar ac. Gynecol Oncol. 2024 Feb;181:162-169. doi: 10.1016/j.ygyno.2023.12.004. Epub 2024 Jan 11. Gynecol Oncol. 2024. PMID: 38211393 Free article. Clinical Trial.
Molecular profiles of endometrial cancer tumors among Black patients.
Wilhite AM, Baca Y, Xiu J, Paladugu R, ElNaggar AC, Brown J, Winer IS, Morris R, Erickson BK, Olawaiye AB, Powell M, Korn WM, Rocconi RP, Khabele D, Jones NL. Wilhite AM, et al. Among authors: elnaggar ac. Gynecol Oncol. 2022 Jul;166(1):108-116. doi: 10.1016/j.ygyno.2022.04.014. Epub 2022 Apr 28. Gynecol Oncol. 2022. PMID: 35490034
38 results